Skip to main content
. 2017 Mar 21;29(3):184–195. doi: 10.1097/CCO.0000000000000366

FIGURE 1.

FIGURE 1

Immunotherapy Single-agent Clinical Trials of atezolizumab, nivolumab, pembrolizumab, avelumab, and durvalumab in various stages of development further subdivided by disease state, into nonmuscle-invasive bladder cancer, muscle-invasive bladder cancer, metastatic first line, and metastatic second line.